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Abstract: The availability of a once-a-year zoledronic acid infusion heralds a new era in 
the management of osteoporosis. It virtually eliminates the problem of poor compliance with 
orally administered bisphosphonates and, because it bypasses the gastrointestinal tract, it is 
not   associated with gastrointestinal side effects. Zoledronic acid is effective for the   treatment 
and prevention of postmenopausal osteoporosis, and for the treatment of osteoporosis in 
men, and   glucocorticoid-induced osteoporosis. When administered within three months of 
a hip fracture, it reduces mortality and the risk of subsequent fractures. It is remarkably free 
of serious adverse effects. After   administration of the intravenous infusion, about 18% of 
bisphosphonate-naïve patients   experience an acute-phase reaction, including low-grade tem-
perature, aches, and pains. This is reduced to about 9% in those who have been treated with 
oral bisphosphonates, and is   further reduced by the concomitant and subsequent administration 
of acetaminophen. The   likelihood and magnitude of the acute-phase reaction is less after the 
second infusion. Other adverse effects are similar to those encountered with other bisphospho-
nates. Because it is mostly excreted by the kidneys, zoledronic acid should not be administered 
to patients with a creatinine clearance less than 35 mL/min. It should not be administered to 
patients with hypocalcemia.
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Introduction
The main problem with osteoporosis is that it is a silent disease, frequently   unnoticed 
until a fracture occurs. There are no warning signs. Unfortunately, an   osteoporotic 
fracture is often a life-changing event, and the mortality and morbidity associated 
with fractures, especially at the hip, is considerable. Regrettably, even under the best 
  circumstances, many patients who have sustained osteoporotic   fractures, especially at the 
hip, are not able to resume their daily activities. Osteoporosis is characterized by a low 
bone mass and microarchitectural deterioration, resulting in an increased   susceptibility 
to fractures. It is very common, with about 40% of white women and 13% of white men 
aged 50 and older expected to sustain an osteoporotic fracture.1–3
The prevalence of osteoporotic fractures in women exceeds the combined   prevalence 
of breast cancer, stroke, heart failure, and myocardial infarction in women.4 The esti-
mated economic impact of osteoporosis-related fractures is staggering. In the US in 
2005, over two million fractures were sustained, costing about $17 billion. About 70% 
of these fractures occur in people aged 65 years and older, and these are responsible 
for about 87% of the total cost.5Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Diagnosis of osteoporosis
Diagnosis of osteoporosis can be established solely based on 
the presence of fragility, low-trauma, or atraumatic fractures. 
A fragility fracture is defined as a fracture sustained after 
  falling from a height that does not exceed the body height. 
Low-trauma or low-energy fractures occur after trauma 
that would not have been anticipated to result in a fracture. 
  Atraumatic fractures occur spontaneously in the absence 
of trauma, as may happen while the person is sitting down 
and suddenly experiences very severe localized back pain 
as a result of a vertebral compression fracture. It is also 
  possible that, in some instances, an atraumatic hip fracture is 
  responsible for the fall a patient with osteoporosis sustains, as 
opposed to the fall causing the fracture. It has been suggested 
that the torque force applied to the femoral neck while the 
patient is turning may be enough to induce a hip fracture.
Many vertebral compression fractures are asymptomatic, 
and the patient presents with no severe back pain, only loss 
of height or kyphosis. The presence of these asymptomatic 
vertebral compression fractures, however, is also   diagnostic 
of osteoporosis and substantially increases the risk of 
  subsequent vertebral and other fractures.
Osteoporosis can also be diagnosed by bone densitometry 
of the hip, lumbar vertebrae, or the radius (distal one-third) as 
per World Health Organization (WHO) guidelines.6 A T-score 
of -2.5 or lower establishes the densitometric diagnosis of 
osteoporosis. The T-score refers to the number of standard 
deviations the patient’s bone mineral density (BMD) is from 
the mean compared with that of a healthy young adult refer-
ence population of the same gender. Patients with a T-score of 
-1.0 or higher are classified as having a normal bone density, 
and those with a T-score less than -1.0 and higher than -2.5 
are classified as having osteopenia.
Patients with osteopenia also have an increased   fracture risk. 
It is, however, intuitive that a patient with a T-score of -2.4 has 
a higher fracture risk than one with a T-score of -1.1, although 
both are in the same diagnostic category of   osteopenia. To 
estimate the fracture risk better, the WHO released its Fracture 
Risk Assessment (FRAX®) tool in   February 2008. This tool 
estimates the probability of an osteopenic patient sustaining 
a hip or a major osteoporotic fracture within the following 10 
years. This probability, expressed as a percentage, is deter-
mined based on the BMD and a series of risk factors including 
current cigarette and alcohol use, glucocorticoid usage, and 
other factors.7 The FRAX® tool is freely available, at no cost, 
on the Internet. The National Osteoporosis Foundation has 
issued guidelines recommending that treatment be considered 
in patients with osteopenia if a threshold is reached, ie, a 3% 
and 20% probability of sustaining a hip or other major frac-
tures, respectively, within the following 10 years.8
The ease of diagnosing osteoporosis and selecting patients 
who need to be treated, and the availability of medication 
that can significantly alter the natural course of osteoporosis 
and substantially reduce the fracture risk, mandate that an 
all-out effort be made to identify patients at risk of sustaining 
fractures before they actually sustain a fracture. Regrettably, 
however, many patients who have sustained an osteoporotic 
hip fracture and had it surgically repaired are not treated 
for osteoporosis, even though the increased risk of subse-
quent fractures is well known. The American Orthopaedic 
  Association has developed the Own the Bone® program in 
an attempt to remedy this situation.9
Osteoporosis medications
Patients needing treatment
The final decision to treat or not to treat, and which particular 
therapy to use, must be the treating clinician’s decision, based 
on the circumstances and needs of the patient. However, as 
a general rule, it is recommended that the following receive 
medical treatment:
•	 Patients with fragility fractures
•	 Patients with a densitometric diagnosis of osteoporosis 
(T-score -2.5 or lower at the total hip, femoral neck, 
lumbar vertebrae, or distal one-third radius)
•	 Patients with osteopenia and a FRAX® score of $3% 
or $20% for hip and other major osteoporotic fractures, 
respectively.
Secondary causes of osteoporosis should first be identified 
and corrected, especially hypovitaminosis D. For optimum 
results, in addition to specific medications, the   therapeutic 
strategy must include an adequate daily   calcium and   vitamin D 
intake, as well as lifestyle changes, such as   physical exercise 
for sedentary patients and the   discontinuation of cigarette 
smoking in smokers. In older patients, the fracture risk is 
reduced and overall outcome is improved by reducing the 
risk and impact of falling. Hip protectors may be a useful 
tool in this arena.
Compliance with medication  
for an asymptomatic condition
One important issue to consider is the patient’s compliance 
with long-term intake of a medication for an essentially 
asymptomatic condition. The very low bioavailability of 
orally administered bisphosphonates necessitates a stringent 
routine that often interferes with the patient’s regular daily 
routine, ie, the patient must take the oral bisphosphonate Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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while fasting, with a glass of water, and must refrain from 
eating, drinking, taking any other medication, lying down, 
or undertaking any activity that may increase the risk of 
gastroesophageal reflux, for 30 minutes (alendronate or 
risedronate) or 60 minutes (ibandronate).
Many patients will not comply with this regimen, espe-
cially given that patients may often have other medications 
that need to be taken in the fasting state. Compliance is also 
low in patients who experience adverse effects, such as the 
upper gastrointestinal symptoms commonly associated with 
oral bisphosphonates. Patients with cognitive   impairment 
also may not be able to take the medication exactly as 
directed. Similarly, in nursing homes and other institutions, it 
may not be possible to expect the nursing staff to ensure that 
all patients take the bisphosphonate exactly as they should.
There are ample data to support the poor   compliance of 
patients with intake of oral bisphosphonates and the direct 
correlation between compliance and improved outcome.10–12 
The US Surgeon General has indeed   identified poor 
  compliance with therapy as a major obstacle in the 
  successful management of osteoporosis and reducing the 
risk of fractures.13 Patients prefer less frequent dosing 
regimens and intravenous (IV) infusion to the oral intake of 
bisphosphonates.10,14 These are now becoming available.
Chemical structure  
of bisphosphonates
All bisphosphonates share the same basic chemical structure of 
two phosphonic acid molecules linked to a carbon molecule. 
They also have two side chains which determine the affinity 
of the bisphosphonate for the calcium phosphate in hydroxy-
apatite crystals in bone tissue, and determine the extent to 
which the bisphosphonate inhibits the bone-resorbing activity 
of osteoclasts by selectively inhibiting the farnesyl pyrophos-
phate synthase (FPPS) enzyme, the key regulatory enzyme 
in the mevalonic acid pathway. This prevents downstream 
protein prenylation which, in turn, inhibits the bone-resorbing 
activity of osteoclasts, and leads to osteoclast apoptosis. It also 
interferes with the formation of osteoclasts.15 Differences in 
these two side chains are responsible for the clinical difference 
observed between the various bisphosphonates. The affinity of 
zoledronic acid for hydroxyapatite is higher than that of other 
bisphosphonates, and the inhibition of FPPS is higher than that 
seen in other bisphosphonates.16
Zoledronic acid
Zoledronic acid has a nitrogen-containing heterocyclic ring 
as a side chain, and can be administered by IV infusion once 
a year, virtually eliminating compliance issues. Improved 
compliance is associated with improved fracture protection.17 
A cost-effectiveness study conducted in France documented 
that over a three-year period, zoledronic acid was more 
  cost-effective than current therapeutic strategies when 
medication cost, medical visits, monitoring, and   fracture 
management are all taken into consideration.18
Pharmacokinetics
Maximum plasma concentrations of zoledronic acid are 
reached, as expected, at the end of the IV infusion. Blood 
levels then rapidly decline to less than 10% at four hours 
and to less than 1% at 24 hours after infusion. About 61% 
of the administered dose is taken up rapidly by bone tissue, 
tending to localize in areas of increased turnover rate, and is 
then slowly released back into the circulation. The   remaining 
39% is excreted unchanged via glomerular filtration by 
the   kidneys without a significant component of tubular 
secretion.19 The elimination of zoledronic acid is triphasic, 
comprising two rapid phases followed by a long terminal 
elimination half-life of 146 hours.15,20
Zoledronic acid clearance is dependent on the patient’s 
creatinine clearance. When compared with subjects   having 
normal renal function (creatinine clearance above 80 mL/min), 
the area under the concentration curve is about 15% higher 
in patients with mild renal impairment (creatinine clearance 
50–80 mL/min) and 43% higher in those with moderate renal 
impairment (creatinine clearance between 30–50 mL/min). 
Zoledronic acid administration is not recommended in 
those with a creatinine level below 35 mL/min. There is no 
need to adjust the dose in patients who have a creatinine 
  clearance of 35 mL/min or higher. Zoledronic acid does not 
inhibit the P450 enzyme, and there is   therefore no interac-
tion with other medications   metabolized via   cytochrome 
P450.21 However, caution should be exercised in patients 
on medications that have the potential of reducing the serum 
calcium level, such as loop diuretics and   aminoglycosides, 
and potentially   nephrotoxic medications, such as nonsteroidal 
anti-  inflammatory compounds.
Pharmacodynamics
Zoledronic acid selectively inhibits the FPPS enzyme, 
which leads to a loss of prenylated proteins in osteoclasts 
and reduced bone resorbing activity.22 This is manifested by 
a reduced concentration of bone resorption markers in the 
serum and urine.
A subset analysis of patients included in the Health 
Outcomes and Reduced Incidence with Zoledronic Acid Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
324
Hamdy
Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) showed 
that when compared with placebo, annual IV infusion of 
zoledronic acid induced a median decrease of 50% in beta-
C-terminal telopeptides of Type 1 collagen (beta-CTx) and 
a 30% decrease in bone-specific alkaline phosphatase (ALP) 
in 604 patients (305 on placebo and 299 on zoledronic acid), 
and a 56% decrease in procollagen Type 1 amino-terminal 
peptides (PINP) in 1245 patients (627 on placebo and 618 on 
zoledronic acid). In most patients these levels remained 
within the premenopausal range before the next infusion. 
Levels below the premenopausal range, however, were seen in 
1.7%, 17.8%, and 19% for ALP, CTx, and PINP, respectively. 
The third infusion of zoledronic acid led to a 60% reduction of 
CTx levels within 9–11 days; this was followed by a gradual 
increase, indicating the persistence of bone resorption in 
patients receiving zoledronic acid. No association could be 
found between low PINP levels at the end of the first year 
and fracture risk.23
In another subset of the HORIZON-PFT, 152 patients 
underwent a bone biopsy at three years. Compared with 
placebo, patients receiving zoledronic acid had a higher tra-
becular number, higher trabecular bone volume, decreased 
trabecular separation, and a trend toward improvement in 
connectivity density. There were no signs of adynamic bone 
tissue.24
Clinical efficacy
Postmenopausal osteoporosis
Zoledronic acid is effective at reducing the risk of fractures 
in women with postmenopausal osteoporosis (Table 1). Over 
a three-year period, the HORIZON-PFT demonstrated a 
41% reduction in the cumulative incidence of hip fractures 
(P = 0.0024), a 70% reduction of new morphometric vertebral 
fractures (P , 0.001), and a 25% reduction in nonvertebral 
fractures (P , 0.001, see Figure 1).25
Compared with placebo, the changes in BMD induced 
by zoledronic acid were 6%, 5.1%, and 6.7% in the total hip, 
femoral neck, and lumbar vertebrae, respectively. Similarly, 
compared with placebo, the biochemical markers of bone 
  turnover were significantly reduced in the zoledronic acid 
group. At 12 months, the levels of serum CTx, bone-specific 
ALP, and N-terminal propeptide of Type I collagen were 59%, 
30%, and 58% lower, respectively, in the zoledronic acid group 
than in the placebo group (P , 0.001 for all groups).25
The HORIZON-PFT was a double-blind, randomized, 
placebo-controlled study which included 7736 postmeno-
pausal women between the ages of 65 and 89 years recruited 
from 239 clinical centers in 27 countries. Patients included in 
the trial either had a T-score of -2.5 or lower at the femoral 
neck or a T-score of -1.5 or lower, in addition to radio  logical 
evidence of either one moderate vertebral compression frac-
ture or two mild vertebral compression fractures.
Patients were randomly allocated to either a placebo 
or an active group (zoledronic acid 5 mg) administered by 
IV   infusion at baseline, year 1, and year 2. The follow-up 
period was three years. There were two subgroups of patients; 
in the first (3045 active and 3039 placebo), no   concomitant 
osteoporosis therapy was allowed, and in the second 
(830 active and 822 placebo), selective estrogen receptor 
modulators, calcitonin, hormonal replacement therapy, or 
tibolone were allowed at baseline and during the study.
A subgroup analysis of postmenopausal women aged 
75 years and older included in the HORIZON-PFT study 
showed that zoledronic acid leads to a significant reduction in 
clinical fractures, emphasizing the effectiveness and potential 
role of zoledronic acid in the management of osteoporosis 
in older patients.26
Although no head-to-head study with fractures as the 
endpoint has been conducted, the efficacy of zoledronic acid 
in reducing hip fractures has been established.27,28
Glucocorticoid-induced osteoporosis
The HORIZON-PFT glucocorticoid-induced osteoporosis 
(GIO) trial29 was a noninferiority study comparing zoledronic 
acid with oral risedronate, which demonstrated that, at the end 
of a one-year follow-up period, zoledronic acid was not inferior 
to oral risedronate (5 mg daily orally) in the prevention and 
treatment of GIO (Table 1). The primary endpoint was the 
percentage change in BMD at the lumbar spine. Secondary 
endpoints included the change in BMD at the proximal femur 
and distal radius, and changes in biochemical bone markers.
Two subgroups of patients were included in this study, ie, 
those who had been on glucocorticoids for three months or 
less (prevention subgroup) and those who had been on gluco-
corticoids for more than three months (treatment   subgroup). 
In the latter subgroup, 545 subjects were included (368 
women and 177 men) of mean age 53.0 (± 13.8) years; in the 
prevention subgroup 288 subjects were included (200 women 
and 88 men) of mean age 57.2 (± 15.1) years. Overall, 93% 
of the enrolled subjects completed the study.
Zoledronic acid increased BMD at the lumbar 
vertebrae more than risedronate in both the treatment 
subgroups (by 4.06%, standard error of measurement 
[SE] 0.28 versus 2.71%, SE 0.28) and in the prevention 
subgroup (2.60%, SE 0.45 versus 0.64%, SE 0.46). Other 
bones scanned also showed that zoledronic acid was Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 1 incidence of fractures during the 3-year study period.7 The primary end points – the incidence of morphometric vertebral fracture (Panel A) and the 3-year 
incidence of hip fracture (Panel B) – are shown for both groups. in Panel A, the 5675 patients in stratum 1 who were included in the analysis underwent radiography at 
baseline and at least once during follow up. Any missing data for earlier visits were imputed from later visits, and missing data for later visits were imputed from earlier visits. 
The total number of  follow up radiographs were 5675 at 1 year, 5308 at 2 years, and 4969 at 3 years. Secondary end points – nonvertebral fracture (Panel C), any clinical 
fracture (Panel D), and clinical vertebral fracture (Panel e) – are also shown over a 3-year period. in panels B, C, D, and e, the number of subjects at 36 months is the number 
who had closeout visits on or after the start of the 36-month window for visits.
Reproduced with permission from Black DM, Delmas PD, eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 
2007;356:1809–1822.25 © 2007 Massachusetts Medical Society. All Rights Reserved.
more effective at increasing BMD than risedronate. The 
difference between the two treatment groups was evident 
at six months. Changes in biochemical markers of bone 
resorption demonstrated that zoledronic acid induced a 
more substantial inhibitory effect on bone turnover than 
did risedronate.
Although the overall occurrence of adverse effects was 
higher in the zoledronic acid group, the frequency of   serious Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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adverse effects was similar in both drug groups. Many of the 
patients reported adverse effects associated with   zoledronic 
acid which occurred during the first few days after the   infusion, 
and were consistent with the acute-phase reaction associated 
with IV administration of large doses of   bisphosphonates. 
Seven deaths occurred during the trial, including four on 
zoledronic acid and three on risedronate; none was attributed 
to the study drug. No case of osteonecrosis of the jaw (ONJ) 
or of delayed or nonunion of fractures was reported.
Annual infusions of zoledronic acid are effective at 
  preventing and treating GIO, and have the advantage of 
avoiding compliance and other issues associated with the 
intake of oral bisphosphonates.
Following hip fracture
Zoledronic acid reduces the rate of fractures in men and women 
who have sustained an osteoporotic hip fracture (Table 1). 
The HORIZON-Recurrent Fracture Trial (HORIZON-RFT) 
studied the effects of administering zoledronic acid to patients 
who had recently sustained a hip fracture. In this randomized, 
double-blind, placebo-controlled trial, 2127 patients who had 
sustained a hip fracture within the past 90 days were   randomly 
allocated to either placebo (1062 patients, 802 women and 
260 men) or zoledronic acid (1065 patients, 817 women and 
248 men). Mean ages were 74.6 (± 9.86) years and 74.4 (+ 9.48) 
years in the placebo and zoledronic acid groups, respectively. 
Patients were   followed up for a median of 1.9 years. Compared 
with placebo, patients receiving zoledronic acid had a 35% 
reduction (P = 0.001) of any new clinical fracture (1.7% and 
3.8% in the zoledronic acid and placebo groups, respectively, 
P = 0.02) and the rates of new nonvertebral fractures were 
7.6% and 10.7% in the zoledronic acid and placebo groups, 
respectively (P = 0.03). Overall mortality was also significantly 
less in the zoledronic acid than in the placebo group (9.6% and 
13.3%, respectively), representing a 28% mortality   reduction 
(P = 0.01).30
A subsequent analysis of the HORIZON-RFT when the 
time interval between fracture repair surgery and administra-
tion of zoledronic acid was taken into account revealed that 
  administration of zoledronic acid two weeks or more after 
surgical repair of the fracture was associated with signifi-
cant reductions in clinical vertebral, nonvertebral, and hip 
fractures, as well as increased hip BMD.31 Results of this 
study point to the   possibility of administering zoledronic 
Table 1 indications for zoledronic acid based on selected published studies
Indication Postmenopausal  
osteoporosis25
Post-hip fracture30 Glucocorticoid-induced Osteoporosis20,29 
Name of study
HORiZON-PFT HORiZON-RFT
HORiZON-GiO
Prevention Treatment
Study type Double-blind;  
randomized
Double-blind;  
randomized
Double-blind, randomized;  
non-inferiority
Control Placebo Placebo Risedronate
Duration (yrs) 3 3 1
Number included 7,736 2,127 288 545
Age (yrs):  
mean/range
Placebo  
Zoledronate
73.0 ± 5.4
73.1 ± 5.34
Placebo 
Zoledronate
74.6 ± 9.86  
74.4 ± 9.48
57.2 ± 15.1 53.0 ± 13.8
inclusion criteria
T # -2.5 or  
T # -1.5 and vertebral fx
Osteoporotic hip fx in the  
previous 3 months
Glucocorticoid therapy duration
#3 months .3 months
end point Fractures  
Bone mineral density  
Bone markers
Fractures  
Mortality
Bone mineral density  
Bone markers
Fracture risk  
reduction vs 
control
Hip fx  
vertebral (morph) fx  
New vertebral fx
41%
70% 
25%
New clinical fx 35%  N/A
BMD vs  
control
Total hip  
Femoral neck  
Lumbar vertebrae
6%
5.1%
6.7%
N/A
Lumbar vertebrae
Zoledronate 2.6%  
Risedronate 0.6% 
    Zoledronate 4.1%  
    Risedronate 2.7%
Mortality N/A 28% N/A
Abbreviations: HORiZON, Health Outcomes and Reduced incidence with Zoledronic Acid Once Yearly; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial; GiO, 
Glucocorticoid-induced Osteoporosis; fx, fracture; Lv, lumbar vertebrae; BMD, bone mineral density; N/A, not applicable.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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acid to patients hospitalized for hip or other osteoporotic 
fractures while still in hospital,32 thus significantly improving 
compliance and outcome.
Men with osteoporosis
Men are not immune to osteoporosis. In fact, the outcome after a 
hip fracture tends to be worse in men than in women. Current esti-
mates indicate that in the US there are presently at least 14 million 
men with osteoporosis or low bone mass, and that men sustain 
about 500,000 osteoporosis-related fractures every year.33
A two-year, noninferiority, randomized,   multicenter, dou-
ble-blind, active-controlled clinical trial which included 302 
men with osteoporosis (including   osteoporosis   secondary to 
hypogonadism) with a mean age of 64 (range 25–86) years 
showed that zoledronic acid was not inferior to the weekly 
oral bisphosphonate used (Table 2). At the end of the two-
year follow-up period, the mean increase in lumbar vertebral 
BMD was 6.1% and 6.2% in the zoledronic acid and oral 
bisphosphonate groups, respectively. The   overall mortality 
and adverse effect were comparable in both groups.20
Prevention of postmenopausal 
osteoporosis
Zoledronic acid is approved for the prevention of 
osteoporosis in women with osteopenia (Table 2). The 
dosage is 5 mg administered by IV infusion every two 
years.34 To assess the usefulness of zoledronic acid in 
the management of osteopenia, a 24-month, randomized, 
double-blind, placebo-controlled trial was conducted in 
581 postmenopausal women, 45 years of age or older, with 
evidence of osteopenia as manifested by a T-score less than 
-1.0 and higher than -2.5. Zoledronic acid was adminis-
tered just once at the time of randomization to 181 women 
and once a year to 198 women, while 202 women received 
placebo infusions.
Compared with placebo, women receiving zoledronic acid 
showed a significant increase in BMD of +5.18% (95% confi-
dence interval [CI] 4.64–5.71) and +4.42% (95% CI 3.87–4.97) 
in those receiving the annual dose and those receiving the 
single dose, respectively. Those on placebo infusion sustained 
a decrease in the BMD at the lumbar vertebrae of -1.32% (95% 
CI 1.85–0.80). Significant increases in hip BMD were also noted 
in women receiving zoledronic acid compared with placebo. 
As expected, in the women receiving zoledronic acid there was 
an initial decrease in markers of bone turnover, followed by a 
gradual partial recovery. Zoledronic acid infusions were well 
tolerated. The overall incidence of serious adverse events was 
similar in the three groups, being 10.9%, 9.4%, and 11.4% in 
the group on zoledronic acid once, zoledronic acid annually, 
and placebo, respectively. The adverse events were similar to 
those noted in other larger trials. As expected, the incidence of 
adverse effects was less after the second dose of zoledronic acid. 
Table 2 indications for zoledronic acid, based on selected as yet unpublished studies
Indication Men20,33 Prevention20,34,35
Name of study Unpublished Unpublished
Study type
Non-inferiority; 
randomized
Double-blind;  
randomized
Control Alendronate* Placebo
Duration (yrs) 2 2
Number included 302 224 357
Age
Mean 64 years  
Range 25–86 years
$45 years
inclusion criteria
  Osteopenia  
,5 yrs postmenopause
Osteopenia  
$5 yrs postmenopause
end point Bone mineral density Bone mineral density
Fracture risk  
Reduction vs control
N/A N/A
BMD vs control
Zoledronate 
Alendronate
6.1%  
6.2%
Zoledronate  Lv – 4.0%  
 Hip – 2.6%  
Lv – 2.2%  
 Hip – 2.1%
 Zoledronate  Lv – 4.8%  
Hip – 2.1% 
Placebo  Placebo Lv – 0.7%  
Hip – 1.0%
Mortality N/A N/A
*As cited by Piper33 regarding the HORiZON study mentioned in Reclast20 which does not name the active control.
Abbreviations: BMD, bone mineral density; Lv, lumbar vertebrae; N/A not available.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Of note, no case of atrial fibrillation (AF), ONJ, or long-term 
negative effect on renal function was reported.35
Bone loss induced by cancer treatment
A number of medications used in the management of cancer 
induce bone loss. Osteoporosis may complicate antiestrogen 
therapy in women with hormone-sensitive breast cancer and 
androgen deprivation therapy in men with prostate cancer. 
Zoledronic acid counteracts this bone loss.36 It also reduces 
the skeletal-related events associated with bone metastases 
in patients with breast or prostate cancer37,38 and, in addition, 
may have specific anticancer activity.37
In women with breast cancer, aromatase inhibitors 
increase bone turnover and reduce bone mass by about 
4%–5% over a two-year period. Compared with tamoxifen, 
the risk of fracture is increased by 35%–50% in women treated 
with aromatase inhibitors.39 Several studies have documented 
the beneficial effect of zoledronic acid in the management of 
bone loss resulting from therapy for cancer.40–44
In a study of 93 men with prostate cancer receiving 
androgen deprivation therapy, zoledronic acid was shown to 
increase BMD significantly compared with placebo, regard-
less of whether the patients had been on androgen deprivation 
therapy for less or more than one year. In the former group 
(50 patients), the change in BMD at 12 months was +5.95% 
and -3.23% in the zoledronic acid and placebo groups, 
respectively (P = 0.0005). Similarly, among those who had 
been on androgen deprivation therapy for more than one year, 
the changes in BMD at 12 months were +6.08% and +1.58% 
in the zoledronic acid and placebo groups, respectively 
(P = 0.0005).45 Several other studies have shown comparable 
results for efficacy of zoledronic acid in men receiving andro-
gen deprivation therapy.46–49
Other disease states associated with  
a low bone mass and osteoporosis
A number of small studies confirm the efficacy of zoledronic 
acid in various disease states. Zoledronic acid has been 
shown to prevent the bone loss seen in 62 adult patients who 
had received a liver transplant for chronic liver disease.50 
Zoledronic acid has also been shown to reduce and possibly 
reverse the bone loss often incurred by stroke victims who 
develop hemiplegia, especially in the paralyzed side.51–53 
Additionally, in a study on 30 human immunodeficiency virus 
(HIV)-infected patients (27 men and 3 women), zoledronic 
acid was effective at managing HIV-associated osteopenia or 
osteoporosis.54 Zoledronic acid also significantly improved 
the BMD at the lumbar vertebrae and hips of 54 patients 
with monoclonal gammopathy of undetermined significance 
and may be effective for the prevention of fractures in these 
patients.55 Finally, several small studies have confirmed the 
usefulness of zoledronic acid in the management of osteopo-
rosis in patients with thalassemia.56–58
Adverse effects
Acute-phase reaction
The acute-phase reaction is characterized by a low-grade 
fever associated with fatigue, malaise, generalized aches 
and pains, and, occasionally, bone pain and arthralgia 
occurring 24–36 hours postinfusion and gradually subsiding 
over the following 2–3 days.59 The acute-phase response is 
dose-dependent, and occurs mostly after the first infusion of 
zoledronic acid in a bisphosphonate-naïve patient. It is much 
less pronounced in subsequent infusions and in patients who 
have previously taken oral bisphosphonates.60 Its severity 
can also be reduced by administration of acetaminophen 
500–1000 mg or paracetamol just before and for 24–48 hours 
after the infusion (Figure 2). Administration of nonsteroidal 
anti-inflammatory compounds is not routinely recommended 
because of the risk of renal impairment. The acute-phase 
reaction has also been seen following the administration of 
IV and oral bisphosphonates, albeit to a much lesser extent 
and degree of severity.61 Patients should be made aware of this 
potential adverse effect and advised to take acetaminophen 
should symptoms arise.
Musculoskeletal pain
There have been a few reports of patients experiencing severe 
incapacitating musculoskeletal pain in the lower back, pelvis, 
hips, upper legs, and ribs after taking IV or oral (weekly or 
monthly dose, but not daily dose) bisphosphonates.62 The 
US Food and Drug Administration (FDA) has issued an 
alert to this effect.63 These musculoskeletal pains are differ-
ent from the acute-phase reaction. Severe musculoskeletal 
pain can occur at any time after the administration of the 
bisphosphonate, but tends to improve in many patients after 
discontinuation of therapy, although it may linger on in some 
patients, even after discontinuation.
The exact mechanism of these musculoskeletal pains has 
not been delineated. It could be related to vitamin D   deficiency 
and the compensatory secondary   hyperparathyroidism which 
maintains a high degree of bone turnover and increases the 
uptake of bisphosphonate in bone, resulting in a higher than 
average concentration of bisphosphonate in the bone microen-
vironment. This, in turn, would lead to increased production 
of interleukin-6 and other proinflammatory   cytokines, which Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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will potentiate the effect of elevated interleukin-6 due to 
secondary hyperparathyroidism.58,64 Other causes of acute 
musculoskeletal pain could be related to bisphosphonate-
associated synovitis,65 flare-up of osteoarthritis,66 or acute 
polyarthritis and myalgia.67
Arrhythmias and atrial fibrillation
In the HORIZON-PFT, arrhythmias occurred in 6.9% 
(n = 266) of patients on zoledronate as compared with 5.3% 
(n = 203) patients on placebo (P = 0.003).68 Serious AF was 
an unexpected finding, occurring in 50 (1.3%) patients on 
zoledronic acid as compared with 20 (0.5%) patients on 
placebo (P , 0.001). In 47/50 patients who developed AF, 
the event occurred more than 30 days after the infusion, 
excluding the possibility that AF was due to hypocalcemia or 
other electrolyte disturbance induced by administration of the 
bisphosphonate.68
Subsequent studies have shown that other bisphosphonates, 
including alendronate, are also associated with AF. More patients 
with AF had previously used alendronate (6.5%) than controls 
(4.1%, P = 0.03).69 In the HORIZON-RFT, AF was reported 
in 2.8% of those receiving zoledronic acid and 2.6% of those 
receiving placebo; similarly, serious AF was reported in 1.1% 
and 1.3% of the treatment and placebo groups, respectively.
Because the HORIZON study (like all other pivotal   fracture 
studies) was not designed to examine the occurrence of AF, 
doubt could be cast on the reliability of the reported data on 
AF,70 especially given that arrhythmias tend to occur more 
frequently in older patients. Possible mechanisms by which bis-
phosphonates may predispose to AF have been described.68
On 12 November 2008, a press release from the FDA 
announced that it could not establish a clear relationship 
between bisphosphonate therapy and AF, that health care 
professionals should not alter their prescribing habits for 
bisphosphonates, and patients should not stop taking these 
medications because of concern about AF.71
Nephrotoxicity
Annual infusions of zoledronate over a three-year period did not 
result in any significant deterioration of renal function.25,72 There 
was nevertheless a transient increase in serum   creatinine levels of 
more than 0.5 mg/dL in 1.3% of patients on zoledronic acid as 
opposed to 0.4% on placebo. Within 30 days, however, the level 
in more than 85% of patients had returned to the preinfusion 
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level.72 Because approximately one-third of the zoledronic acid 
dose administered IV is excreted by glomerular filtration, it is 
not recommended to administer this drug to patients who have 
a creatinine   clearance of less than 35 mL/min. It is also recom-
mended that the IV infusion time be at least 15 minutes.
Atypical fractures  
of the femoral diaphysis
There have been several reports of low-trauma fracture of 
the femoral shaft in patients who have been on long-term 
(2.5–8 years) bisphosphonate therapy.73–77 Bone biopsies 
revealed excessive suppression of bone turnover, and heal-
ing was delayed or absent in many patients. Most of the 
patients who sustain these fractures experience prodromal 
thigh pain or vague discomfort for several weeks or months 
before the   fracture occurs, suggesting that the fracture may 
result from the propagation of a stress fracture that has not 
been able to heal. The majority of patients who have sus-
tained these fractures also had one or more   predisposing 
factors, such as chronic corticosteroid use, diabetes mel-
litus, and severe osteoarthritis of the hip or knee. The 
total   incidence of these fractures was 2.5 per 100,000 
person-years. The   incidence, however, was 0.8 per 100,000 
person-years in a population aged 15–60 years and 7.8 per 
100,000   person-years for people aged 60 years or older. It 
has therefore been   recommended that patients who have 
been on   bisphosphonate therapy for longer than two years be 
instructed that pain in the groin or upper thigh may be pro-
dromal of a femoral diaphysis fracture and that they should 
seek medical help should they experience this pain.60
Bisphosphonate-associated  
osteonecrosis of the jaw
Several terms are used to refer to this condition, including 
ONJ, bisphosphonate-related ONJ, bisphosphonate-induced 
ONJ, and bisphosphonate-associated ONJ. In order to reduce 
ambiguity and promote international uniformity, an Expert 
Panel of the American Dental Association recommended 
use of the term bisphosphonate-associated osteonecrosis of 
the jaw (BON).
There is still no consensus on the definition of BON. The 
common denominators of the various proposed definitions 
include an area of exposed, nonhealing bone in the mandible 
or maxilla in patients who have been on bisphosphonates 
and have not received radiation therapy to the jaw. The 
exposed bone and adjacent area may be asymptomatic or 
may become secondarily infected. Patients may present with 
pain, swelling, paresthesia, suppuration, soft tissue ulceration 
in tissue adjacent to the ragged bony margins of the lesion, 
intra- and extraoral sinus tracks, loosening of the teeth, 
and in severe cases, loss of a significant part of the mandible 
or maxilla.78 Whereas the American Society for Bone and 
Mineral Research (ASBMR), and the American Academy 
of Oral and Maxillofacial Surgeons (AAOMS) stipulate 
that the bone should be exposed for at least eight weeks, the 
American Dental Association (ADA), the Australian and 
New Zealand Bone and Mineral Society (ANZBMS) and the 
Medical Oncology Group of Australia stipulate that the bone 
should be exposed for only six weeks or more. The American 
Association of Endodontists and the American College of 
Rheumatology do not stipulate any time limit. The majority 
of reported cases have followed teeth extraction or other 
dental procedures, although a few cases have been reported 
to have occurred spontaneously in patients with osteoporosis 
treated with oral bisphosphonates.79 The ASBMR task force 
recommends first excluding other common conditions, such 
as mucositis, gingivitis, periodontal disease, sinusitis, caries 
infection, and osteomyelitis.80
The AAOMS has defined three stages of ONJ:78,81 
Stage 1, exposed or necrotic bone in asymptomatic patients 
with no evidence of infection; Stage 2, superimposed infec-
tion as evidenced by pain and erythema in the region of 
the exposed bone, with or without purulent drainage; and 
Stage 3, same findings as for Stage 2, in addition to   pathologic 
  fracture, extraoral fistula, and/or osteolysis extending to the 
inferior border.
The Expert Panel of the ADA79 concluded that, although 
still early in the investigative stage, there appears to be a 
causal relationship between bisphosphonate exposure and 
BON, as evidenced by the strength of the association (the 
incidence is higher among individuals on bisphosphonates), 
temporal association (exposure to bisphosphonates precedes 
BON), biologic gradient (higher doses are associated with 
more rapid and serious presentation of BON), consistency 
(BON has been reported by several investigators), speci-
ficity (BON is seen in patients with cancer, osteoporosis, 
and Paget’s disease), and biologic plausibility (BON is 
defined by the mechanism of action of bisphosphonates, and 
  inhibition of angiogenesis and bone formation after dental 
extraction).
It is, however, debated whether the initial damage in 
ONJ starts in the bone and then spreads to the surrounding 
soft tissues (“inside-out” hypothesis), or whether it starts in 
the oral epithelium and mucosa, and then spreads to the soft 
tissue and eventually to bone (“outside-in” hypothesis).78 
Bisphosphonate toxicity to mucosal cells is well known, as Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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evidenced by the gastric, esophageal, and even oral erosions 
complicating the intake of oral bisphosphonates.82–85 It is 
therefore possible that the pathology starts in the oral mucosa 
and then spreads to the deeper tissues and bone.
On the other hand, proponents of the inside-out hypoth-
esis suggest that if the rate of bone turnover is   substantially 
reduced, repair of microfissures may be impaired, and this may 
increase susceptibility to bone necrosis. An   antiangiogenic 
effect of bisphosphonates has been suggested as a possible 
mechanism leading to BON, whereby interference with blood 
supply may lead to bone necrosis.86 Several studies have 
documented that bisphosphonates inhibit angiogenesis.87 
While this explanation is plausible for cases affecting the 
mandible, it is difficult to explain the relatively frequent 
involvement of the maxilla with its rich blood supply; 26% 
of cases have involved only maxillary bone, and 9% involved 
both the maxilla and mandible.88 It is possible therefore that 
the etiology of BON is multifactorial.89
Several cases have been reported, mostly among patients 
with cancer treated with large doses of IV bisphosphonates. 
A review of 368 BON cases reported in the medical   literature 
for 1996–2006 showed primary diagnoses of multiple 
myeloma (n = 171), metastatic breast cancer (n = 143), 
metastatic prostate cancer (n = 23), and other metastatic 
neoplasia (n = 13). Only 18 cases occurred in patients without 
cancer, ie, three treated for Paget’s disease and 15 treated 
for osteoporosis. In other words, in this large series of 
368 patients, only 15 (4.1%) had received bisphosphonates 
for osteoporosis.88
ONJ, defined as exposed bone in the maxillofacial area 
for more than six weeks with delayed healing despite appro-
priate care, was observed in two of 7714 patients enrolled in 
HORIZON-PFT. One patient was in the active group receiv-
ing zoledronic acid and the other was in the placebo group. 
The condition of both patients improved after appropriate 
antibiotic therapy, debridement, or both.90 The investigators 
concluded that BON is rare in otherwise healthy postmeno-
pausal osteoporotic women treated with zoledronic acid, and 
that there is no evidence to suggest that these patients need 
any special treatment beyond routine dental care, or to support 
altering standard treatment guidelines. An examination of the 
oral cavity before prescribing bisphosphonates is prudent and 
does not have to be conducted by a dental professional.
A reduced rate of bone turnover, as evidenced by low 
serum bone markers levels, such as serum beta-CTx, may 
predispose to ONJ, and therefore assaying these levels may 
be helpful in identifying patients susceptible to BON.91 On the 
other hand, cases of BON have been reported in patients with 
normal CTx levels,92 and the presently available data do not 
support the use of serum CTx to assess the risk of BON.61
The exact risk of developing BON is not known. In a pro-
spective study in Australia where cases were identified based 
on the presence of exposed bone for six weeks or more and 
verification of drug prescriptions, the incidence associated 
with oral alendronate use was in the range 0.01%–0.04%, 
and this risk was increased by more than four-fold in patients 
undergoing dental extraction. The median time of alendronate 
use prior to onset of BON was two years,93 although most 
cases occur after prolonged therapy. Risk factors predis-
posing to BON include advanced age, corticosteroid use, 
rheumatoid arthritis, diabetes mellitus, tooth extraction, 
invasive dental procedures, and smoking.94 The majority 
of reported BON cases occurred in patients receiving large 
doses of IV bisphosphonate as part of cancer therapy. The 
risk/benefit ratio of BON versus fractures in patients with 
osteoporosis is in favor of treating such patients, and this 
should be explained to interested patients. In patients who are 
about to undergo major dental work, it is prudent to postpone 
the initiation of bisphosphonate therapy until after the dental 
work has been completed. It is also advisable to examine the 
gums prior to initiating bisphosphonate therapy. Several task 
forces and expert panels have developed recommendations 
for the prevention of BON.81,95,96
Ocular adverse effects
Although rare, ocular inflammation occurs in a small minor-
ity of bisphosphonate-treated patients, who may present with 
ocular pain, photophobia, and/or impaired vision. Nonspecific 
conjunctivitis is usually benign, self-limiting, and improves 
without specific therapy.60 Uveitis and scleritis, on the other 
hand, are serious complications. Very few cases of poste-
rior scleritis and anterior uveitis complicating zoledronic 
acid therapy have been reported.97–101 Ocular complications 
are idiosyncratic, and may occur shortly after, or weeks, 
months, or even years after the initiation of bisphosphonate 
therapy.61,102 Given the potential implications of these con-
ditions, urgent ophthalmologic referral is recommended for 
patients who present with eye symptoms.
Hypocalcemia and secondary 
hyperparathyroidism
Nitrogen-containing bisphosphonates are potent inhibitors of 
osteoclastic bone resorption. By reducing bone resorption, 
they reduce the mobilization of calcium from bones to the 
circulation. Their administration therefore may lead to 
hypocalcemia, which in turn leads to secondary hyperpara-Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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thyroidism, which increases renal tubular calcium resorption 
and activates the 1-alpha hydroxylase enzyme in the kidneys. 
The 25-hydroxyvitamin D in the kidneys is then hydroxylated 
to 1,25 dihydroxyvitamin D as a compensatory method of 
increasing the gastrointestinal absorption of calcium, thus 
restoring serum calcium levels to the normal range.
Patients with hypovitaminosis D, parathyroid dysfunction, 
or renal failure may not be able to correct the hypocalcemia, 
which then becomes symptomatic. It is therefore important to 
ensure that patients about to be administered a bisphospho-
nate, especially via the IV route, are not vitamin D-deficient 
and that they have an adequate daily intake of calcium and 
vitamin D. If there are any concerns, it may be prudent to 
assay serum 25-hydroxyvitamin D, parathyroid hormone, 
calcium, and phosphorus levels.   Bisphosphonate-induced 
hypocalcemia and secondary hyperparathyroidism may be 
avoided or attenuated by the administration of vitamin D 
and calcium supplements. Secondary hyperparathyroidism 
should be avoided, especially in patients with cancer, because 
parathyroid hormone may promote tumor growth.103
Upper gastrointestinal adverse effects
Upper gastrointestinal adverse effects are one of the main 
factors limiting the use of oral bisphosphonates. Because 
zoledronic acid is IV administered, it bypasses the gastroin-
testinal tract, so these adverse effects are rarely seen.
Practical points
indications and dosage
Zoledronic acid is approved for the treatment and   prevention 
of postmenopausal osteoporosis, osteoporosis in men, GIO, 
and prevention of a second hip fracture in patients who have 
sustained a first hip fracture. The treatment dose is 5 mg IV 
annually, and the prevention dose is 5 mg IV every other year. 
Contraindications include:
•	 Hypocalcemia at the time of infusion
•	 Hypersensitivity to zoledronic acid, any bisphosphonate, 
or any components of zoledronic acid
•	 Patients with a creatinine clearance less than 35 mL/min
•	 Pregnant or nursing mothers
•	 Patients on other forms of zoledronic acid
Administration
Zoledronic acid 5 mg in 100 mL aqueous solution should 
be administered by IV infusion via a vented infusion line, 
administered over at least 15 minutes. Serum calcium and 
creatinine clearance should be checked prior to the infusion. 
Patients with hypocalcemia or a creatinine clearance of 
less than 35 mL/min should not receive the infusion. There 
is no need to adjust the dose for patients with a creatinine 
clearance above 35 mL/min. It is also advisable to assay 
the serum 25-hydroxyvitamin level to ensure the patient 
does not have hypovitaminosis D. A dental examination 
should be performed to ensure that the patient is not in 
need of any major dental work. This does not have to be 
done by a dental professional. Adequate hydration should 
be ensured by instructing the patient to drink at least two 
glasses of water or other fluids before the infusion. Patients, 
especially bisphosphonate-naïve ones, should be appraised 
of the possible acute-phase reaction and alerted that taking 
acetaminophen beforehand might minimize these effects. 
Administration of acetaminophen following the infusion may 
reduce the incidence of the acute-phase reaction. Adequate 
hydration should be maintained, as well as an adequate daily 
calcium and vitamin D intake.
Conclusions
The availability and effectiveness of annual zoledronate 
infusion for the treatment of osteoporosis heralds a new 
era in the management of osteoporosis, because it virtually 
eliminates the compliance problem. It is especially helpful 
if the administration of zoledronic acid can be done at the 
same time as the patient undergoes some other medical 
check-up or procedure, such as a bone density scan or 
mammography.
The positive effect of zoledronate in the prevention of 
fractures after the patient has sustained a hip fracture intro-
duces the concept of administering it while the patient is 
hospitalized for an osteoporotic fracture. This will reduce the 
number of patients who sustain an osteoporotic fracture and 
are neither diagnosed nor treated for osteoporosis.
The need for an IV infusion may deter a few patients, 
particularly in geographic areas where IV infusions are not 
frequently administered, and the patient may need to be 
referred to a secondary medical center.
Although no head-to-head fracture trial has been performed, 
the efficacy of zolendrate is at least as good, if not superior, to 
other treatment modalities. Apart from the acute-phase reaction, 
the incidence of adverse effects is relatively low and benign. 
Renal functions are maintained, and atrial fibrillation, although a 
concern, does not appear to be directly related to the medication. 
BON is rare. Patient acceptance of zoledronic acid is good.
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